How UCB beat 2 other bidders to land $1.9B buyout of Zogenix and its epilepsy drug
Days before it would nail down the FDA’s approval for its epilepsy drug Fintepla, Zogenix received one of the first inquiries from a pharma company about pursuing a potential partnership to market the drug in the EU and other geographies outside the US.
But it wasn’t until the OK came through, in late June, that eventual buyer UCB made initial contact, according to an SEC filing detailing the background leading up to the deal.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 153,800+ biopharma pros reading Endpoints daily — and it's free.